New drug is 'champagne moment' for cystic fibrosis

By Andy Coghlan A PIONEERING drug has drastically improved the lung function of people with one type of cystic fibrosis. It is the first to target the cause, not the symptoms, of the world’s most common hereditary lung disease, and combined with a second drug could improve the lives of tens of thousands around the world. Peter Mueller, chief scientific officer for Vertex Pharmaceuticals in Cambridge, Massachusetts, and colleagues gave the drug, called VX-770, or a placebo to 161 people with cystic fibrosis for a year. At the outset,
  • 首页
  • 游艇租赁
  • 电话
  • 关于我们